Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Personal Products Industry Analysis

UpdatedJun 17, 2026
DataAggregated Company Financials
Companies110
  • 7D2.7%
  • 3M3.7%
  • 1Y-14.4%
  • YTD-8.0%

Over the last 7 days, the Personal Products industry has risen 2.7%, driven by gains from Kenvue of 2.8%. Meanwhile, SL Science Holding actually underperformed within the industry, shrinking 8.4% in the last week. In the past year, the industry is down 14%. Looking forward, earnings are forecast to grow by 33% annually.

Industry Valuation and Performance

Has the U.S. Personal Products Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 17 Jun 2026US$85.1bUS$48.3bUS$700.6m17.2x121.4x1.8x
Fri, 15 May 2026US$78.0bUS$48.2bUS$792.8m16.4x98.3x1.6x
Sun, 12 Apr 2026US$76.1bUS$48.2bUS$613.7m20.8x124x1.6x
Tue, 10 Mar 2026US$86.4bUS$48.2bUS$789.9m23.6x109.4x1.8x
Thu, 05 Feb 2026US$95.6bUS$47.8bUS$369.6m22.1x258.6x2x
Sat, 03 Jan 2026US$89.4bUS$47.6bUS$351.1m21.9x254.7x1.9x
Mon, 01 Dec 2025US$86.3bUS$47.6bUS$357.6m23.2x241.4x1.8x
Wed, 29 Oct 2025US$89.1bUS$47.7bUS$290.4m20.8x306.8x1.9x
Fri, 26 Sep 2025US$89.4bUS$47.6bUS$307.5m21.1x290.7x1.9x
Sun, 24 Aug 2025US$101.2bUS$47.6bUS$303.9m21.8x333.1x2.1x
Tue, 22 Jul 2025US$101.1bUS$48.0bUS$109.7m18.6x921.4x2.1x
Thu, 19 Jun 2025US$96.1bUS$48.0bUS$108.3m17.4x887.9x2x
Sat, 17 May 2025US$93.6bUS$48.0bUS$114.5m21.5x817.6x1.9x
Mon, 14 Apr 2025US$82.7bUS$48.7bUS$555.1m22.9x149x1.7x
Wed, 12 Mar 2025US$95.8bUS$49.0bUS$330.9m26x289.4x2x
Fri, 07 Feb 2025US$90.0bUS$49.0bUS$541.4m26.9x166.3x1.8x
Sun, 05 Jan 2025US$95.7bUS$49.3bUS$1.5b25.6x64.8x1.9x
Tue, 03 Dec 2024US$103.5bUS$49.3bUS$1.5b29.8x70.2x2.1x
Thu, 31 Oct 2024US$105.7bUS$49.5bUS$1.6b25.6x65.3x2.1x
Sat, 28 Sep 2024US$112.7bUS$49.5bUS$1.6b25.8x68.9x2.3x
Mon, 26 Aug 2024US$112.1bUS$49.5bUS$1.6b21.9x70.4x2.3x
Wed, 24 Jul 2024US$107.2bUS$49.0bUS$2.4b22.3x44.3x2.2x
Fri, 21 Jun 2024US$111.6bUS$49.0bUS$2.4b22.6x46x2.3x
Sun, 19 May 2024US$122.6bUS$48.8bUS$2.5b21.6x50x2.5x
Tue, 16 Apr 2024US$120.8bUS$48.8bUS$2.5b25.1x47.6x2.5x
Thu, 14 Mar 2024US$134.0bUS$48.7bUS$2.5b25.2x53.4x2.8x
Sat, 10 Feb 2024US$127.8bUS$49.2bUS$2.6b26.4x49.8x2.6x
Mon, 08 Jan 2024US$124.8bUS$49.9bUS$2.6b25.1x47.4x2.5x
Wed, 06 Dec 2023US$122.9bUS$49.9bUS$2.6b26.5x47.2x2.5x
Fri, 03 Nov 2023US$101.1bUS$49.7bUS$2.8b23.7x35.5x2x
Sun, 01 Oct 2023US$122.1bUS$50.0bUS$3.3b23.4x37.1x2.4x
Tue, 29 Aug 2023US$132.2bUS$50.0bUS$3.3b20.1x40.4x2.6x
Thu, 27 Jul 2023US$147.6bUS$49.8bUS$3.1b25.6x48.2x3x
Sat, 24 Jun 2023US$152.1bUS$49.3bUS$3.1b22.8x48.6x3.1x
Price to Earnings Ratio

48.6x


Total Market Cap: US$152.1bTotal Earnings: US$3.1bTotal Revenue: US$49.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Personal Products Industry Price to Earnings3Y Average 172.1x202420252026
Current Industry PE
  • Investors are pessimistic on the American Personal Products industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 121x which is lower than its 3-year average PE of 172x.
  • The 3-year average PS ratio of 2.2x is higher than the industry's current PS ratio of 1.8x.
Past Earnings Growth
  • The earnings for companies in the Personal Products industry have declined 39% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Consumer Staples industry?

US Market2.32%
Consumer Staples1.36%
Personal Products2.70%
Personal Products2.70%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
KVUE KenvueUS$18.432.8%
+US$979.2m		-14.0%PE21.8x
ELF e.l.f. BeautyUS$66.9320.2%
+US$669.3m		-46.7%PE151.2x
EL Estée Lauder CompaniesUS$87.581.2%
+US$369.0m		17.1%PS2.1x
EPC Edgewell Personal CareUS$22.659.3%
+US$88.5m		-0.6%PS0.5x
IPAR InterparfumsUS$100.171.8%
+US$57.8m		-24.6%PE19x

Latest News

EPC
US$22.65
Edgewell Personal Care
7D
9.3%
1Y
-0.6%
Seeking Alpha • 16h

Edgewell: How Exiting Feminine Care Makes It A Buy Opportunity

Summary Edgewell Personal Care is rated Buy, with a $30/share target, following its strategic exit from the feminine care segment and debt reduction. EPC's focus on high-margin wet shaving, sun, and men's grooming segments, especially CREMO's 38% growth, is driving a leaner, more profitable business model. Short-term margin pressures from inflation and tariffs are expected to ease in H2 as restructuring and productivity initiatives reach full effect. Key risks include inflationary shipping/material costs, factory consolidation execution, and Q3's heavy reliance on seasonal sun care sales. Read the full article on Seeking Alpha
COTY
US$2.07
Coty
7D
3.0%
1Y
-58.1%
Analysis Article • 21h

Coty (COTY) Stock Could Be 79% Below Fair Value After Portfolio Review

Coty (COTY) has moved to address recent challenges by rolling out its Coty Curated framework and reviewing its portfolio, while leaning into Gen Z interest in fragrance wardrobes and a resilient beauty market. See our latest analysis for Coty. Against that backdrop, Coty’s 7 day share price return of 5.67% contrasts with a year to date share price decline of 34.08% and a 1 year total shareholder return decline of 59.41%, suggesting recent interest has picked up after a tougher run. If you are...
NAGE
US$3.43
Niagen Bioscience
7D
-2.3%
1Y
-75.3%
Narrative Update • Jun 16

NAGE: Injectables And Expanded Clinical Access Will Support Future Buyback Upside

Niagen Bioscience's analyst price target has been reduced by a combined $5 across recent reports as analysts factor in updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples, while maintaining a fair value estimate of $12.60. Analyst Commentary Recent research on Niagen Bioscience highlights a mix of optimism about the company’s long term potential and caution around the assumptions that underpin the current fair value estimate of $12.60.
ELF
US$66.93
e.l.f. Beauty
7D
20.2%
1Y
-46.7%
LFVN
US$6.04
LifeVantage
7D
-36.3%
1Y
-52.2%
EL
US$87.58
Estée Lauder Companies
7D
1.2%
1Y
17.1%
Narrative Update • Jun 15

EL: Turnaround Progress And Restructuring Charges Will Frame Future Standalone Upside

Analysts have trimmed their price target for Estée Lauder Companies slightly to $95.12 from $95.43. This reflects updated assumptions around revenue growth, profit margins and a modestly higher future P/E multiple.
IPAR
US$100.17
Interparfums
7D
1.8%
1Y
-24.6%
Seeking Alpha • Jun 10

Interparfums: A Fine Fragrance Machine, But 2026 Is A Bridge Year

Summary Interparfums remains a high-quality fragrance company with a diversified license portfolio, strong cash flows, and a conservative balance sheet. 2026 guidance projects flat sales ($1.48B) and lower EPS ($4.85), tempering near-term growth expectations and justifying a Hold rating. Q1 2026 results confirmed solid gross margins (65.1%) and cash flow discipline, but operating margins contracted due to rising SG&A expenses. At ~19x 2026E EPS and a base-case fair value of $89, IPAR offers balanced risk/reward; existing holders can wait, but new buyers should seek a better entry or growth clarity. Read the full article on Seeking Alpha
NATR
US$20.08
Nature's Sunshine Products
7D
-0.3%
1Y
34.9%
KVUE
US$18.43
Kenvue
7D
2.8%
1Y
-14.0%
Narrative Update • Jun 08

KVUE: Future Returns Will Reflect Merger Progress And Legal Earnings Balance

Analysts slightly lifted their fair value estimate for Kenvue to $19.50, a modest move supported by small tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, even as recent Street research from Citi, Barclays and UBS reflects more cautious price targets. Analyst Commentary Recent price target trims of around $1 from several firms signal that the Street is fine tuning expectations rather than making a wholesale shift in its view on Kenvue.
MED
US$11.27
Medifast
7D
-7.5%
1Y
-16.5%
Narrative Update • Jun 06

MED: Leadership Transition And Margin Outlook Will Shape Balanced Future Profile

Analysts have modestly adjusted their price target on Medifast, reflecting updated views on the discount rate, expected profit margins near 8.1%, and an anticipated P/E around 9.7x, which together suggest a slightly different risk and valuation profile for the stock. What's in the News The board has appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026.
BRBR
US$8.83
BellRing Brands
7D
4.7%
1Y
-85.9%
Narrative Update • Jun 04

BRBR: Protein Adoption Trend Will Support Recovery After Recent Earnings Reset

Analysts have cut their price targets on BellRing Brands sharply, with one high profile reduction to $13 from $34 and a series of other target trims and downgrades following a disappointing quarter, rising concerns about competition, and ongoing estimate revisions. Analyst Commentary Recent Street research around BellRing Brands points to a clear reset in expectations, with multiple bearish analysts cutting price targets and, in some cases, downgrading ratings after the latest quarterly report.
HLF
US$11.82
Herbalife
7D
4.6%
1Y
49.8%
Narrative Update • Jun 03

HLF: Refinancing And Margin Improvement Will Support Turnaround Despite Weak EBITDA Guidance

Narrative update on Herbalife Analysts have raised their price target on Herbalife by $2, citing research that points to updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts raising their price target by US$2 are signaling a more constructive view on how Herbalife’s valuation lines up with its fundamentals.
NUS
US$5.05
Nu Skin Enterprises
7D
-7.2%
1Y
-35.0%
Analysis Article • May 18

Nu Skin Enterprises' (NYSE:NUS) Profits May Not Reveal Underlying Issues

The market shrugged off Nu Skin Enterprises, Inc.'s ( NYSE:NUS ) solid earnings report. We did some digging and believe...
NHTC
US$2.03
Natural Health Trends
7D
-11.4%
1Y
-56.3%
DSY
US$5.34
Big Tree Cloud Holdings
7D
-25.8%
1Y
-79.3%